LW-02 Immunopheresis
Advanced, refractory triple-negative breast cancer (TNBC)
Key Facts
About Immunicom
Immunicom is pioneering a disruptive, device-based immunotherapy platform that works outside the body to filter immunosuppressive factors from the blood. Its lead program targets refractory cancers, with initial CE Mark approval in Europe for advanced triple-negative breast cancer and FDA Breakthrough Device designation. The company is advancing a global clinical trial strategy across multiple oncology indications and exploring applications in autoimmune and inflammatory diseases, positioning its technology as a potential backbone for combination therapies.
View full company profileAbout Immunicom
Immunicom is pioneering a disruptive, device-based immunotherapy platform that works outside the body to filter immunosuppressive factors from the blood. Its lead program targets refractory cancers, with initial CE Mark approval in Europe for advanced triple-negative breast cancer and FDA Breakthrough Device designation. The company is advancing a global clinical trial strategy across multiple oncology indications and exploring applications in autoimmune and inflammatory diseases, positioning its technology as a potential backbone for combination therapies.
View full company profileAbout Immunicom
Immunicom is pioneering a disruptive, device-based immunotherapy platform that works outside the body to filter immunosuppressive factors from the blood. Its lead program targets refractory cancers, with initial CE Mark approval in Europe for advanced triple-negative breast cancer and FDA Breakthrough Device designation. The company is advancing a global clinical trial strategy across multiple oncology indications and exploring applications in autoimmune and inflammatory diseases, positioning its technology as a potential backbone for combination therapies.
View full company profileAbout Immunicom
Immunicom is pioneering a disruptive, device-based immunotherapy platform that works outside the body to filter immunosuppressive factors from the blood. Its lead program targets refractory cancers, with initial CE Mark approval in Europe for advanced triple-negative breast cancer and FDA Breakthrough Device designation. The company is advancing a global clinical trial strategy across multiple oncology indications and exploring applications in autoimmune and inflammatory diseases, positioning its technology as a potential backbone for combination therapies.
View full company profileAbout Immunicom
Immunicom is pioneering a disruptive, device-based immunotherapy platform that works outside the body to filter immunosuppressive factors from the blood. Its lead program targets refractory cancers, with initial CE Mark approval in Europe for advanced triple-negative breast cancer and FDA Breakthrough Device designation. The company is advancing a global clinical trial strategy across multiple oncology indications and exploring applications in autoimmune and inflammatory diseases, positioning its technology as a potential backbone for combination therapies.
View full company profile